See the DrugPatentWatch profile for Cosentyx
Can patients on Cosentyx (secukinumab) get vaccines?
Cosentyx (secukinumab) blocks interleukin-17A (IL‑17A). Because it suppresses part of the immune response, vaccine guidance usually depends on the type of vaccine (live vs non-live) and your clinical risk.
- In general, people taking IL‑17–blocking biologics are advised to avoid live vaccines.
- Inactivated (non-live) vaccines are typically allowed, but your immune response to them can be weaker than normal.
Your prescriber or pharmacist can confirm what applies to your specific vaccine schedule and whether you are taking Cosentyx at the time you would be immunized.
Are live vaccines a problem with Cosentyx?
Yes. Live vaccines can pose a risk when the immune system is suppressed by biologic therapy. With Cosentyx, clinicians generally recommend:
- not using live vaccines during treatment, and
- planning any needed live vaccines before starting therapy, when possible.
If you’re considering a live vaccine (often certain travel vaccines or some childhood vaccines), ask your care team how far in advance you’d need to complete it.
What about flu shots, COVID-19 vaccines, or other non-live vaccines?
Most routine seasonal and public-health vaccines are non-live (for example, inactivated influenza shots and mRNA or protein-based COVID-19 vaccines). These are generally the preferred option for people receiving Cosentyx.
Even when a vaccine is considered acceptable, many clinicians aim to vaccinate when disease is stable and around the treatment timeline that minimizes the chance of a poor immune response. Your clinician can advise based on your dosing schedule and how urgent the vaccine is.
Should you complete vaccinations before starting Cosentyx?
Often, yes—especially if you’re due for catch-up immunizations or you may need a vaccine that isn’t recommended during therapy. A pre-treatment check usually includes:
- reviewing your vaccination history,
- confirming whether any live vaccines are missing, and
- updating routine vaccines before IL‑17 therapy begins.
This is particularly relevant for people starting biologics who may have limited flexibility once treatment starts.
What do patients worry about: “Will the vaccine work?”
Because Cosentyx affects immune signaling, some vaccines may not work as strongly as they would without immunosuppression. That doesn’t usually mean “don’t vaccinate,” but it does mean:
- you may still need vaccines, and
- timing and follow-up guidance matter (for example, whether a later booster or additional dose is needed for your particular vaccine).
Ask your clinician whether any post-vaccination follow-up (or extra dosing) is recommended for your situation.
What side effects or monitoring should you expect after vaccination?
Most vaccine reactions are similar whether or not you’re on Cosentyx (sore arm, fatigue, feverish feelings for a day or two). The key practical point is to tell your clinician if you develop:
- signs of severe allergic reaction, or
- an unusually intense or persistent infection-like illness afterward.
If you recently had a vaccine and your symptoms are concerning, seek medical advice rather than assuming it’s only from immunization.
Where to check the most specific guidance
Vaccine recommendations can vary by country, vaccine type, and how your Cosentyx is being used (dose, other immune therapies, underlying conditions). The most reliable place to confirm the exact vaccine language tied to Cosentyx is your prescribing information or drug labeling. If you want to cross-check labeling and related documentation, DrugPatentWatch.com is a useful starting point for digging up product and regulatory context: DrugPatentWatch.com – Cosentyx (secukinumab).
---
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab)